Knock-down of HEXA and HEXB genes correlate with the absence of the immunostimulatory function of HSC-derived dendritic cells

Cell Biochemistry and Function

Volumn 30, Issue 1, 2012, Pages 61-68

  Tiribuzi, Roberto ^a   D'Angelo, Francesco ^a   Berardi, Anna C ^b   Martino, Sabata ^a   Orlacchio, Aldo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Beta Hexosaminidase; Cell differentiation; Denfritic cell; Haemopoietic stem cell; RNA interference

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; BETA N ACETYLHEXOSAMINIDASE ALPHA CHAIN; BETA N ACETYLHEXOSAMINIDASE BETA CHAIN; HEXA PROTEIN, HUMAN; HEXB PROTEIN, HUMAN;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELLULAR IMMUNITY; DENDRITIC CELL; GENE SILENCING; GENETIC DISORDER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; PRIORITY JOURNAL; RNA INTERFERENCE; SANDHOFF DISEASE; TAY SACHS DISEASE; CD4+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; GENETICS; GM2 GANGLIOSIDOSIS; IMMUNOLOGY; INFLAMMATION; METABOLISM; STEM CELL;

BETA-HEXOSAMINIDASE ALPHA CHAIN; BETA-HEXOSAMINIDASE BETA CHAIN; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; GANGLIOSIDOSES, GM2; GENE KNOCKDOWN TECHNIQUES; HUMANS; INFLAMMATION; STEM CELLS;

EID: 84855338426     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1819     Document Type: Article

References (43)

1. Gravel RA, Kabak MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The GM2 gangliosidoses. In The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, Vogelstein B (eds.). McGraw-Hill: New York, 2001; 3827-3876.
2. Kolter T, Sandhoff K. Sphingolipid metabolism diseases. BBA 2006; 1758: 2057-2079.
3. Tsuji D, Akeboshi H, Matsuoka K, et al. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Ann Neurol 2011; 69: 691-701.
4. Masciullo M, Santoro M, Modoni A, et al. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis 2010. DOI: 10.1007/s10545-010-9186-3
5. Matsuoka K, Tamura T, Tsuji D, et al. Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 Gangliosidosis. Mol Ther 2011; Apr 12. DOI:10.1038/mt.2011.27
6. Martino S, Emiliani C, Tancini B, et al. Absence of metabolic cross-correction in Tay-Sachs cells: implications for gene therapy. J Biol Chem 2002; 277: 20177-20184.
7. Martino S, Marconi P, Tancini B, et al. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 2005; 14: 2113-2123.
8. Martino S, di Girolamo I, Cavazzin C, et al. Neural precursor cell cultures from GM2 gangliosidosis animal models recapitulate the biochemical and molecular hallmarks of the brain pathology. J Neurochem 2009; 109: 135-147.
9. Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. PNAS 2000; 97: 10954-10959.
10. Myerowitz R, Lawson D, Mizukami H, Mi Y, Tifft CJ, Proia RL. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet 2002; 11: 1343-1350.
11. Zhou D, Mattner J, Cantu C, 3rd. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306: 1786-1789.
12. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Gröne HJ. Normal development and function of invariant natural killer T cells in mice withisoglobotrihexosylceramide (iGb3) deficiency. PNAS 2007; 104: 5977-5978.
13. McCarthy C, Shepherd D, Fleire S. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Ex Med 2007; 204: 1131-1144.
14. Pei B, Speak AO, Shepherd D. Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids. J Immunol 2011; 186: 1348-1360.
15. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010; 285: 20423-20427.
16. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
17. Karman J, Ling C, Sandor M, Fabry Z. Initiation of Immune Responses in Brain Is Promoted by Local Dendritic Cells. J Immunol 2004; 173: 2353-2361.
18. McMahon EJ, Bailey SL, Miller SD. CNS dendritic cells: critical participants in CNS inflammation? Neurochem Int 2006; 49: 195-203.
19. Ilarregui JM, Rabinovich GA. Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulat 2010; 17: 157-160.
20. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005; 307: 1630-1634.
21. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003; 299: 1400-1403.
22. Martino S, Tiribuzi R, Ciraci E, et al. Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells. Int J Biochem Cell B 2011; 43: 775-783.
23. Della Bella S, Nicola S, Timofeeva I, Villa ML, Santoro A, Berardi AC. Are interleukin- 16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood 2004; 104: 4020-4028.
24. + dendritic cells knocked-down for cathepsin S by RNA interference. Minerva Biotecnologica 2008; 20: 59-67.
25. Martino S, di Girolamo I, Tiribuzi R, D'Angelo F, Datti A, Orlacchio A. Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells. J Biomed Biotechnol 2009. DOI: 10.1155/2009/410260
26. Martino S, di Girolamo I, Cavazzin C, et al. Neural precursor cell cultures from GM2 gangliosidosis animal models recapitulate the biochemical and molecular hallmarks of the brain pathology. J Neurochem 2009; 109: 135-147.
27. Martino S, Tiribuzi R, Tortori A, et al. Specific determination of {beta}-Galactocerebrosidase activity via competitive inhibition of {beta}-Galactosidase. Clin Chem 2009; 55: 541-548.
28. Sopelsa AM, Severini MH, Da Silva CM, Tobo PR, Giugliani R, Coelho JC. Characterization of beta-galactosidase in leukocytes and fibroblasts of GM1 gangliosidosis heterozygotes compared to normal subjects. Clin Biochem 2000; 33: 125-129.
29. Martino S, Emiliani C, Orlacchio A, Hosseini R, Stirling JL. Beta-N-acetylhexosaminidases A and S havesimilar sub-cellular distributions in HL-60 cells. BBA 1995; 1243: 489-495.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analitical Biochemistry 1976; 72: 248-254.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 4: 402-408.
32. Beutler E, Kuhl W, Comings D. Hexosaminidase isozyme in type O Gm2 gangliosidosis (Sandhoff-Jatzkewitz disease). Am J Hum Genet 1975; 27: 628-638.
33. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, James MN. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. J Mol Biol 2006; 359: 913-929.
34. Conzelmann K, Sandhoff K. The specificity of human N-acetyl-beta-D-hexosaminidases towards glycosphincolipids is determined by an activator protein. Adv Exp Med Biol 1980; 125: 295-306.
35. Salio M, Cerundolo V. Linking Inflammation to Natural Killer T Cell Activation. PLoS Biol 2009; e1000226. Epub 2009 Oct 27.
36. Jeyakumar M, Thomas R, Elliot-Smith E, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 2003; 4: 974-987.
37. Taniike M, Yamanaka S, Proia RL, Langaman C, Bone-Turrentine T, Suzuki K. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol 1995; 89: 296-304.
38. Jeyakumar M, Smith D, Eliott-Smith E, et al. An inducible mouse model of late onset Tay-Sachs disease. Neurobiol Dis 2002; 3: 201-210.
39. Sango K, Yamanaka S, Hoffmann A, et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 1995; 2: 170-176.
40. Phaneuf D, Wakamatsu N, Huang JQ, et al. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 1996; 1: 1-14.
41. Pankuweit S, Ruppert V, Maisch B. Inflammation in dilated cardiomyopathy. Herz 2004; 8: 788-793. Review.
42. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154-169. Review.
43. Tiribuzi R, Orlacchio A, Crispoltoni L, et al. Lysosomal β-Galactosidase and β-Hexosaminidase Activities Correlate with Clinical Stages of Dementia Associated with Alzheimer's Disease and Type 2 Diabetes Mellitus. J Alzheimers Dis 2011; Feb 14. DOI: 10.3233/JAD-2011-100525